The aim of the work was to identify Actinomycetes strains that are able to produce high levels of anti-MRSA metabolites with a potential use in curing resistant Staphylococcus aureus infections. Twenty-six endophytic Actinomycetes strains were isolated from various marine invertebrates living in two different marine ecosystems (the Mediterranean Sea and the Red Sea). Among them, Streptomyces sp. RS-9 (obtained from the soft coral Sarcophyton sp. from the Red Sea) and Streptomyces sp. MS-26 (obtained from the jellyfish derived from the Mediterranean Sea) demonstrated the highest antagonistic activity against 18 isolates of methicillin-resistant Staphylococcus aureus (MRSA) and 2 isolates of methicillin-resistant coagulase-negative Staphylococci (MRCoNS). The optimization of culture conditions, which includes the time course (at the 6 th and the 3 rd day of growth), the incubation temperature (27.5EC), pH (8.0 and 6.0), nutritional requirements comprising different metals, carbon (glucose and glycerol, respectively), and nitrogen (mixture of valine with peanut and a mixture of soybean with methionine and asparagines, respectively) sources for RS-9 and MS-26 strains, respectively, resulted in a 2.2-fold and 2.5-fold increase in the productivity of anti-MRSA metabolites. The GC/MS analysis proved the presence of different bioactive compounds in Streptomyces sp. RS-9 and Streptomyces sp. MS-26 extracts. Two pure compounds, A) 1-Methyl-2-acetyl-6-acetoxy-7-methoxy-(1,2,3,4-tetrahydroisoquinoline) and B)-4-(dimethylamino)-1,4,4d,5,12,12a-hexahydro-3,10,11,12a-tetrahydroxy-6-methyl-1,12-dioxo-,[4S-(4-α,4a,al]-(2-naphthacene carboxamide, which is a well-known antibiotic called anhydrotetracycline), were isolated from Streptomyces sp. MS-26. Those compounds possessed potent anti-MRSA activity against all the tested clinical MRSA and MRCoNS isolates. The minimum inhibition concentration (MIC) of the above two compounds ranged from 16 to 1024 μgml !1 and 4 to 128 μgml !1 , respectively. The minimum bactericidal concentration (MBC) ranged from 16 to 1024 μgml !1 and 8 to 128 μgml !1 , respectively with anticancer activity against colon cancer (HCT-16), liver cancer (HepG-2), and lung cancer (A-549) cell lines.